Abstract
Administration of tacrine (THA) for the treatment of Alzheimer's disease results in a reversible hepatotoxicity in 30–50% of patients, as indicated by an increase in transaminase levels. However, the intracellular mechanisms underlying such a toxicity have not yet been elucidated. In this study, we performed short-term and long-term in vitro treatments on primary human and rat hepatocyte cultures as well as on nonparenchymal rat liver epithelial cells (RLEC), known as CYP1A-deficient cells. Cell ultrastructure was analyzed under different conditions and the release of lactate dehydrogenase (LDH) was used to evaluate cytotoxicity. The effects of THA on protein synthesis, intermediary metabolism and reduced glutathione (GSH) level were also determined in rat hepatocytes. THA induced dose-dependent toxic effects in liver parenchymal and nonparenchymal cells, with human hepatocytes being less sensitive. This toxicity appeared to be unrelated to metabolism of THA since similar effects were observed in rat hepatocytes and RLEC, in which THA metabolism was found negligible. Ribosome aggregation appeared only at high concentrations (>1 mmol/L) and was not specific to hepatocytes. Therefore, the THA-induced decrease in protein synthesis observed at lower concentrations was likely not related to this alteration. ATP and glycogen levels as well as GSH content were reduced upon THA. However, while glycogen level decreased at THA doses similar to those inducing an increase in LDH release, the fall in ATP and GSH contents occurred at higher doses. Thus, glycogen level in hepatocytes appeared to be a more sensitive indicator of THA toxicity than were ATP and GSH levels. We also found that protein synthesis started to decrease at THA doses that were still ineffective on LDH release. This might suggest that the decrease in synthesis of one or several proteins upon THA treatment represents the early signal leading cells to death.
Similar content being viewed by others
References
Al Casey S, Brewster D, Viau C, Acosta D. Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of velnacrine maleate. Toxicol Lett. 1995;76:257–65.
Balson R, Gibson PR, Ames D, Bhathal PS. Tacrine-induced hepatotoxicity. Tolerability and management. CNS Drugs. 1995;4:168–81.
Becquemont L, Lecoeur S, Simon T et al. Glutathione S-transferase θ genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics. 1997;7:251–3.
Benoit GG, Naud CF, Simard MA, Astier AL. Noninterference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines. Biochem Pharmacol. 1997;53:423–7.
Berson A, Renault S, Lettéron P et al. Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction. Gastroenterology. 1996;110: 1878–90.
Bezek S, Kukan M, Pool WF, Woolf TF. The effect of cytochromes P4501A induction and inhibition on the disposition of the cognition activator tacrine in rat hepatic preparations. Xenobiotica. 1996;26:935–46.
Buc-Calderon P, Latour I, Roberfroid M. Biochemical changes in isolated hepatocytes exposed to tert-butyl hydroperoxide. Implications for its cytotoxicity. Cell Biol Toxicol. 1991;7: 129–43.
Butterfield DA, Rangachari A. Membrane-altering effects of velnacrine and N-methylacridinium: relevance to tacrine and Alzheimer's disease. Biochem Biophys Res Commun. 1992;185:596–603.
Dogterom P, Nagelkerke JF, Mulder GJ. Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of glutathione and vitamin E. Biochem Pharmacol. 1988;37: 2311–13.
Faa G, Ledda-Columbano GM, Ambu R et al. An electron microscopic study of apoptosis induced by cycloheximide in rat liver. Liver. 1994;14:270–8.
Fariss MW, Johnsen SA, Walton LP, Mumaw VR, Ray SD. Tetrahydroaminoacridine-induced ribosomal changes and inhibition of protein synthesis in rat hepatocyte suspensions. Hepatology, 1994;20:240–6.
Farlow M, Gracon SI, Hershey LA, Lewis KW, Salowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. J Am Med Assoc. 1992;268:2523–9.
Forsyth DR, Sormon DJ, Morgan RA, Wilcock GK. Clinical experience with and side effects of tacrine hydrochloride in Alzheimer's disease: a pilot study. Age Ageing. 1989;18: 223–9.
Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK. Glutathione S-transferase µ genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis. Br J Clin Pharmacol. 1995;39:411–5.
Guguen-Guillouzo C, Clement B, Baffet G et al. Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type. Exp Cell Res. 1983;143:47–54.
Guzelian PS, Bissell DM, Meyer UA. Drug metabolism in adult rat hepatocytes in primary monolayer culture. Gastroenterology. 1977;72:1232–9.
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J Am Med Assoc. 1994;271:985–91.
Ledda-Columbano GM, Coni P, Faa G, Manenti G, Columbano A. Rapid induction of apoptosis in rat liver by cycloheximide. Am J Pathol. 1992;140:545–9.
Lehtonen JYA, Rytömaa M, Kinnunen PKJ. Characteristics of the binding of tacrine to acidic phospholipids. Biophys J. 1996;70:2185–94.
Lerche C, Le Jossic C, Fautrel A et al. Rat liver epithelial cells express functional cytochrome P450 2E1. Carcinogenesis. 1996;17:1101–6.
Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol. 1993;46:13–20.
Monteith DK, Theiss JC. Comparison of tacrine-induced cytotoxicity in primary cultures of rat, mouse, monkey, dog, rabbit, and human hepatocytes. Drug Chem Toxicol. 1996;19:59–70.
Morel-Chany E, Guillouzo C, Trincal G, Szajnert MF. `Spontaneous' neoplastic transformation in vitro of epithelial cell strains of rat liver: cytology, growth and enzymatic activities. Eur J Cancer. 1978;14:1341–52.
O'Brien JT, Eagger S, Levy R. Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. Age Ageing. 1991;20:129–31.
Park BK, Madden S, Spaldin V, Woolf TF, Pool WF. Tacrine transaminitis: potential mechanisms. Alzheimer Dis Assoc Disord. 1994;8:S39–49.
Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol. 1994;38:15–22.
Stachlewitz RF, Arteel GE, Raleigh JA, Connor HD, Mason RP, Thurman RG. Development and characterization of a new model of tacrine-induced hepatotoxicity: role of the sympathetic nervous system and hypoxia-reoxygenation. J Pharmacol Exp Ther. 1997;282:1591–9.
Viau CJ, Curren RD, Wallace K. Cytotoxicity of tacrine and velnacrine metabolites in cultured rat, dog and human hepatocytes. Drug Chem Toxicol. 1993;16:227–39.
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J Am Med Assoc. 1994;271: 992–8.
Rights and permissions
About this article
Cite this article
Lagadic-Gossmann, D., Rissel, M., Le Bot, M. et al. Toxic Effects of Tacrine on Primary Hepatocytes and Liver Epithelial Cells in Culture. Cell Biol Toxicol 14, 361–373 (1998). https://doi.org/10.1023/A:1007589808761
Issue Date:
DOI: https://doi.org/10.1023/A:1007589808761